Infectious Disease Clinical Development Expertise

Getting a novel infectious disease vaccine or treatment on the market today is extremely critical and complex. 

Infectious diseases are a threat to global health and way of life everywhere – particularly in the midst of the current COVID-19 pandemic. Time is of the essence when it comes to developing safe and effective infectious disease vaccines and treatments.  In addition to recent pandemic outbreaks caused by viral infections, more treatment-resistant bacterial and fungal infections are rising, with antibiotics and antifungals becoming less effective.

Our scientific-minded infectious disease experts can help navigate this challenging landscape, having conducted more than 250 programs for Infectious Disease treatments and vaccines.

Experience Battling Infectious Diseases

Whether you are aiming to prevent or combat a viral, bacterial, fungal or parasitic infection, Veristat can help make the difference for your study’s success. Our teams understand the nuances and difficulties involved with treating infectious diseases, have the experience to perform vaccine trials, and are adept with rapid response to global pandemics that arise, such as the current COVID-19 outbreak response.   

At Veristat, our experienced teams are poised to plan and implement these efforts quickly providing:    
Recent Pandemic Experience
Veristat_icon_infectious disease-216

> 250

Clinical trials for infectious disease treatments and vaccines
Veristat_icon_covid-216-2

> 20 COVID-19

vaccines/therapeutics

> 50 Influenza

vaccine programs

8 Ebola

vaccine projects for 2014 outbreak

Explore Our Recent Infectious Disease Experience

Prevention and Treatment of Bacterial & Fungal Infections
  
Acinetobacter Baumannii Infections
   
Gram-Negative Infections
  
Acute Bacterial Skin and Skin Structure Infections (ABSSI) 
   
H. Pylori Infection
  
Bacterial Pneumonia 
   
Joint infection 
  
Botulinum vaccine
   
Methicillin-resistant Staphylococcus aureus (MRSA) Bacteremia 
  
Candidemia 
   
Nasal Infection 
  
Clostridium Difficile (C.Diff) 
   
Nontuberculous Mycobacterial (NTM) Lung Disease
  
Complicated Intra-Abdominal Infections (cIAI) 
   
Nosocomial Infection

 

Prevention and Treatment of Viruses/Viral Infection​
  
COVID 19 ​
   
Influenza- Pandemic ​
  
Cytomegalovirus (CMV) Infection ​
   
Lassa Fever
  
Ebola
   
Malaria
  
Epstein Barr Virus (EBV) ​
   
Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
  
Hepatitis A, B, and C ​
   
Recurrent Respiratory Papillomatosis (RRP)
  
Herpes (HSV2) ​
   
Respiratory Syncytial Virus ​
  
HIV/AIDS ​
   
RNA Vaccine Platforms for multiple types of Infectious Diseases/Cancers ​
  
Human Papilloma Virus (HPV) ​
   
Shingles - Varicella-Zoster Virus (VZV)
  
Influenza - H1N1
  
Smallpox
  
Influenza - H5N1
  
Sexually Transmitted Infections
  
Influenza - Seasonal
  
Typhoid Fever
  
Influenza (Universal Vaccine)
  
West Nile Virus ​

 

white_spacer

Learn More with These Resources

Case Study
Rapid Launch of a Phase I COVID-19 Vaccine Trial

Learn how the Veristat team quickly mobilized to help a sponsor get their clinical trial databased designed and launched in two weeks in order to achieve ...

download
Case Study
Data Collection Efficiency for a Novel Anti-Infective ...

Learn how we improved data collection efficiency through thoughtful database design that allowed the sponsor to overcome a complex trial challenge and transition ...

download
Fact Sheet
COVID-19 Success Guide

As you consider the impact that the COVID-19 pandemic has on your programs, there are some key strategies that could help you maintain momentum, assess your risks and ...

download
Request A Proposal
  • Privacy Policy
  • ©2006 - 2021 Veristat, LLC. All rights reserved. Veristat is a trademark of Veristat, LLC. All other trademarks are the property of their respective owners.